Source: Melanoma News Today, February 2017
The presence of a specific bacteria in the gut of patients with melanoma, as well as a greater diversity of gut bacteria, are associated with a better response to anti-PD-1 immunotherapy.
Understanding this relationship between a patient’s gut bacteria profile and the immune system response could promote new cancer prognosis and treatment strategies.
These findings were presented at the 2017 ASCO-SITC Clinical Immuno-Oncology Symposium, held Feb. 23-25 in Orlando, Fla. The presentation was titled “Association of diversity and composition of the gut microbiome with differential responses to PD-1 based therapy in patients with metastatic melanoma.”read the original full article